These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 25505582)

  • 1. A clinical therapeutic protein drug-drug interaction study: coadministration of denosumab and midazolam in postmenopausal women with osteoporosis.
    Jang G; Kaufman A; Lee E; Hamilton L; Hutton S; Egbuna O; Padhi D
    Pharmacol Res Perspect; 2014 Apr; 2(2):e00033. PubMed ID: 25505582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
    Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
    Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
    Flaherty KT; Lathia C; Frye RF; Schuchter L; Redlinger M; Rosen M; O'Dwyer PJ
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1111-8. PubMed ID: 21350850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study evaluating the effect of everolimus on the pharmacokinetics of midazolam in healthy subjects.
    Urva S; Bouillaud E; Delaney R; Jappe A; Cheung W
    J Clin Pharmacol; 2013 Apr; 53(4):444-50. PubMed ID: 23426978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis.
    Lasco A; Morabito N; Basile G; Atteritano M; Gaudio A; Giorgianni GM; Morini E; Faraci B; Bellone F; Catalano A
    Calcif Tissue Int; 2016 Feb; 98(2):123-8. PubMed ID: 26498169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach.
    Zhuang Y; de Vries DE; Xu Z; Marciniak SJ; Chen D; Leon F; Davis HM; Zhou H
    J Clin Pharmacol; 2015 Dec; 55(12):1386-94. PubMed ID: 26054042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab--an emerging treatment for postmenopausal osteoporosis.
    Lewiecki EM
    Expert Opin Biol Ther; 2010 Mar; 10(3):467-76. PubMed ID: 20095877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab in postmenopausal women with low bone mineral density.
    McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
    N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of osteoporosis with denosumab.
    Lewiecki EM
    Maturitas; 2010 Jun; 66(2):182-6. PubMed ID: 20236778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women.
    Kumagai Y; Hasunuma T; Padhi D
    Bone; 2011 Nov; 49(5):1101-7. PubMed ID: 21871589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs - midazolam and odanacatib.
    Marcantonio EE; Ballard J; Gibson CR; Kassahun K; Palamanda J; Tang C; Evers R; Liu C; Zajic S; Mahon C; Mostoller K; Hreniuk D; Mehta A; Morris D; Wagner JA; Stoch SA
    J Clin Pharmacol; 2014 Nov; 54(11):1280-9. PubMed ID: 24895078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo.
    Ring BJ; Patterson BE; Mitchell MI; Vandenbranden M; Gillespie J; Bedding AW; Jewell H; Payne CD; Forgue ST; Eckstein J; Wrighton SA; Phillips DL
    Clin Pharmacol Ther; 2005 Jan; 77(1):63-75. PubMed ID: 15637532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study.
    Ermer J; Corcoran M; Martin P
    Drugs R D; 2015 Jun; 15(2):175-85. PubMed ID: 25862215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
    Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
    Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-drug interactions and metabolism in cytochrome P450 2C knockout mice: application to troleandomycin and midazolam.
    Grimsley A; Gallagher R; Hutchison M; Pickup K; Wilson ID; Samuelsson K
    Biochem Pharmacol; 2013 Aug; 86(4):529-38. PubMed ID: 23732297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the impact of Polygonum capitatum, a traditional Chinese herbal medicine, on rat hepatic cytochrome P450 enzymes by using a cocktail of probe drugs.
    Zheng L; Lu Y; Cao X; Huang Y; Liu Y; Tang L; Liao SG; Wang AM; Li YJ; Lan YY; Wang YL
    J Ethnopharmacol; 2014 Dec; 158 Pt A():276-82. PubMed ID: 25446640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
    Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.